following the close of the merger agreement. Mallinckrodt and Endo said the location of the combined company’s U.S. headquarters and its corporate name will be announced “in due course.” ...

Mallinckrodt Pharmaceuticals plc and Endo Inc. said Thursday they are combining as part of a stock-and-cash deal with an enterprise value of $6.7 billion that will give both companies a roughly 50 ...

The proposed merger comes nearly a year after Endo emerged from bankruptcy protection. Endo Inc. has entered into an agreement to merge with Mallinckrodt in a cash and stock transaction that ...

Mallinckrodt and Endo are set to merge in a cash-and-stock deal valued at $6.7 billion, with the drug makers set to list shares of the new firm on the New York Stock Exchange.

Mallinckrodt and Malvern, Pennsylvania-based Endo's predecessor company ... Upon completion of the merger, Olafsson will become CEO of the combined company, and Paul Efron, a member of the ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...

Specialty pharmaceutical companies Endo, Inc. (OTC:ENDPQ) and Mallinckrodt (OTC:MNKTQ) announced Thursday plans to combine in a stock and cash transaction worth $6.7B, creating a public firm ...

Per deal terms, Endo shareholders will receive Mallinckrodt stock and a share of $80 million in cash. After the merger, a business made up of Endo’s sterile injectables and both companies ...

"That helps us." Endo shareholders will get $80 million in cash and own 49.9% of the combined company, while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion, the ...

(Sharecast News) - Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal. Under the terms of the agreement, Endo shareholders will receive $80m ...